Patrick D. Campbell
Analyst · Greenwich Consultants. Please go ahead with your question
Thank you George and good morning everyone. As George indicated this quarter, we demonstrated the strength of our portfolio from both a business and geographic perspective. For the second consecutive quarter, we had sales greater than $6 billion. We maintained strong operational discipline while at the same time continue to invest in the business to drive long-term sustainable shareholder value, all consistent with the themes we talked about in last week's investor meeting. As explained in our press release this morning and shown on slide number five, third quarter reported earnings per share were $1.32. Included in this result are two special items, which I would like to explain in some detail for you. First, we made the strategic decision to consolidate our global Flexible Circuits manufacturing operations from two plants, one in Columbia, Missouri, the other in Singapore, and to our Singapore plant, to better serve our customers who are primarily in Asia. Second, as I mentioned during our investor meeting last week, we expect to have a handful of real estate sales over the next several quarters, as we actively manage our real-estate portfolio. During the third quarter, we sold our current lab facility located in Swan, Korea, which happen to be located on a very valuable piece of property. And we are currently building a new state-of-the-art customer-oriented R&D facility closer to Seoul, and many of our major [ph] customers for only 40% of what we sold the property for. After addressing for these two items, the earnings for the third quarter were $1.29 per share. Please refer to today's press release for more detailed discussion for these special items. As we discussed in last quarter's earnings call, generally accepted accounting principles prevent us from classifying the divested pharmaceutical business as a discontinued operation. Therefore it raised a year-on-year comparability issue. Q3 2006 revenues for the Pharmaceutical business were $201 million and operating income excluding special items were $73 million or $0.07 per share. Adjusting for Pharma and special items, earnings per share increased 17.3% year-on-year. On slide number six, we compare our third quarter P&L versus last year's third quarter. As you can see on this slide, our results this quarter are very much in line with our overall goals of accelerating top line growth, maintaining our strong operating margin position, while at the same time investing in growth for the future to drive long-term shareholder value. Excluding special items, earnings per share were $1.29, a year-on-year increase of 10.3% on sales growth of 5.5%. Adjusting for divestures, mainly Pharma, earnings increased17.3% on sales growth of 9.4%. Operating income was up 3.3% to $1.4 billion, or up 9.3% excluding divestures. Gross margin and operating income margin were 47.8% and 22.6% respectively, were in line with last year's third quarter after adjusting for the impact of divestures. R&D and related expenditures were up 10% year-over-year excluding divestures to support our overall strategy to reinvigorate our business core. SG&A expense was up 3.8% year-on-year at $1.2 billion, or up over 9% adjusted for divestures, as we stepped up investments in sales and marketing including an increase in advertising and merchandizing, to drive growth in many of our businesses. Our third quarter tax rate was 30.8% and down 1.9 percentage points versus last year. The lower tax rate in the quarter was principally due to a one-time cumulative impact of tax rate changes for several of our European subsidiaries. We now expect our full year tax rate to be in the range of 32% to 32.5%, as a result of this quarter's lower tax rate. Please turn to slide seven for a recap of our third quarter top-line performance. Worldwide sales in local currency increased 6.3%, with 8% from our international operations and 3.6% from the U.S. Organic volume worldwide was 4.2%, led by 7.1% increase in international. Internationally, Europe turned into another very strong quarter led by safety, security and protection, healthcare and consumer-office business with local currency growth of 11.8%, 8.1% of that was organic. Rounding out international, Latin America and Canada and Asia-Pacific regions saw a local currency growth at 11% and 4.1% respectively. Organic volume growth in the U.S. was up slightly, as strong growth in healthcare and electrical communications was offset by weaknesses in a handful of businesses that are impacted by the slowdown in the U.S. housing, low construction and niche retail markets, mainly our industrial minerals, protective materials, traffic-safety and office-supply businesses. Worldwide, acquisitions contribute 2.1% while prices were flat versus last year's third quarter. Divestitures, primarily Pharma, decreased sales by 3.9% and currency translation added 3.1%. Before we move to the business segment highlights, please refer to slide eight. We would like to comment on our year-to-date performance. Excluding divestitures, mainly Pharma, sales were up 10.4% year-to-date with operating income up 12.5% and earnings per share up over 17%. Capital efficiency is equally important to growth and margins. Our return on capital was 22.2%, up 40 basis points from last year's comparable period adjusted for divestitures, mainly Pharma. As you can see, through nine months, we continue to execute as per plan of accelerating growth, maintaining margins and investment returns, while delivering double-digit earnings growth. Overall our plan continues to remain on-track. Now please turn to slide nine, where I will review our quarterly and year-to-date results by business segment starting with industrial and transportation. Driven by broad-based growth across the portfolio, our industrial and transportation business delivered another great quarter, with sales growth of 9.3% and operating income growth of 11.4%. Sales growth was led by our industrial adhesives and tapes business, followed by automotive OEM, automotive body shop solutions and abrasives businesses. Organic local currency sales increased 4.2% with an additional 1.2% of growth coming from acquisitions. Year-to-date, sales were up 8.2% with operating income growth of 10.7%, as our business continues to drive strong productivity programs with operating margins up 50 basis points year-on-year to 21.3%, a record margin for this business. Some of the products driving growth in the third quarter were specialty chemicals for the oil and gas markets; paint preparation systems that deliver productivity and paint booster body shops; Laminating adhesives providing attachment solutions in industrial applications; and packaging tapes, just to name a few. Strong market penetration in the emerging markets, particularly the BRICP countries continued in the third quarter. Europe, Middle East, Africa as well as Latin American regions all showed strong local currency growth. Industrial transportation business continues to invest in R&D, to strengthen its core technologies or adding strategic complementary acquisitions to boost our core adhesives, tapes and the abrasives platforms and to expand into the adjacent markets. We recently announced the acquisition of Venture Tape Corporation, a global provider of pressure-sensitive adhesive tapes based in Rockland [ph], Massachusetts. Venture Tape manufactures a broad range of tapes using construction, oil and gas, HVAC, electronics, aerospace, marine and appliance markets. This acquisition broadens our pressure-sensitive adhesive tape platform, bringing new channels to 3M and allows us to expand into adjacent markets such as the global construction market. Please turn to slide 10 for a review of third quarter results for Display & Graphics segment. For the third quarter, Display & Graphics sales were up 2% or over $1 billion, a record quarter. Sales growth was negatively impacted by over 2%, due to the divesture of the Opticom and Canoga loop business along with product rationalization in a couple of our other businesses. Local currency growth is 1%. Year-to-date Display & Graphics sales have increased more than 4% with profits up nearly 6%. Our market-leading optical systems business continues to focus on market segmentation with strong penetration in handhelds, computer displays and LCD televisions. We did experience attachment rate loss in LCD desktop monitors and LCD TV segments in Q3, as competition continues to intensify in this market. We also noted a slowing in the mix from 720P to 1080P LCD TVs, which impacts our business as 3M films are used more heavily in 1080P sets. As the market leader, we will continue to compete aggressively, dousing product innovations, price and volumes across the entire brightness-enhancement film product pyramid. This means continued price down to meet our customers cost down requirements. Our continued commitment to invest in this business has led to a solid stream of new products that our customers are very excited about that will allow us to continue to maintain our market leadership in brightness-enhancement films. 3M's brightness-enhancement films provide an environment solution to reduce energy consumption, a rapidly increasing requirement from retail customers and government units. We're also on our schedule in scaling up and improving the productivity of our manufacturing facilities. Commercial Graphics posted another solid quarter with strong sales growth. We saw an uplift in the vehicle-wrapping market where we provide films, inks and other products for this rolling billboard industry. Likewise, in traffic safety systems, we have posted continuous seasonal growth internationally, driven largely by the road construction season. The U.S. highway construction market work slowed in third quarter sequentially from the first half of the year, as the industry is facing substantial material inflation for cement and asphalt, which is driving more of the spend in the construction materials for road servicing versus other spend such as sign sheeting. Please turn to slide 11, where we will discuss the third quarter highlights for our healthcare business. Once again, healthcare had a great quarter with broad-based double-digit growth across all divisions, excluding Pharma. Local currency growth, including acquisitions was 16.6%, with 4.6% coming from acquisitions. Of the remaining organic growth, 4.5% resulted from our recent supply agreements related to the sale of our branded Pharmaceutical business, in which our drug delivery systems business became a supplier to the acquiring companies. Of the 4.6% of growth from acquisitions, much of it came from two deals. Biotrace International, PLC, a U.K.-based provider of microbiology products and SoftMed, a Maryland-based provider of health information software solutions. We also acquired Neoplast, a Bangkok-based manufacturer and distributor of consumer and professional skin and room care products. Excluding Pharma, sales in healthcare were up 20.6% over the third quarter of 2006 and profits were up 13.7%, ex-Pharma to $259 million. Year-to-date margins were 27.7%, overall sales were up 22.7% year-to-date and operating income was up 19.1%, both excluding the sale of Pharma. Within the segment, each business delivered double-digit sales growth. Our drug delivery systems business where we leveraged multiple 3M technologies, global regulatory expertise and manufacturing precision led the way. We also saw strong sales in health information systems, where we are the worldwide expert in healthcare funding and performance management solutions. In dentistry, we continued to deliver a steady stream of new products and have been voted the most innovative dental company, two years in running. In fact, we just recently launched a new product in dental, which is new to the world technology that creates a lower shrinking composite filling material available along our two state-of-the-art adhesives for better bonding and patient comfort. In orthodontics, where Self-Ligating Brackets are the fastest growing segment in the market, 3M's exclusive SmartClip braces system is leading the way and we saw impressive double-digit growth in that business again this quarter. Please turn to Slide 12 for details on our consumer and office business. Consumer and office sales increased 5.9% to $898 million in the third quarter. Local currency sales were up 3.5%, including 1.1% from acquisitions, primarily due to the October 2006 acquisition of Nylonge, a global provider of household cleaning products including cellulose sponges. Profits were $192 million, with operating income margins of 21.3%. The consumer and office business is having outstanding year, with year-to-date sales, up almost 8% and operating profits up 12%. Year-to-date growth is being lead by the consumer mass retail and the do-it-yourself retail of channels; strong growth in homecare and from Scotch-Brite scrubbing products. In construction home improvement, growth came from Filtrete, air filtration for the U.S. residential HVAC systems along with command mounting and fastening products in the third quarter. As previously mentioned, sales growth was tampered by a weakness in the protective materials in the office mass retail channel in the U.S. Geographically 3M's international subsides contributed to drive growth again this quarter, with double-digit growth in all regions led by Europe. During the quarter, we stepped up investment in advertising and merchandising to drive growth from the back-to-school season. We'll continue to invest in advertising during the fourth quarter to accelerate growth during the holiday season. Please turn to slide 13, for a recap of our third quarter performance of our safety, security and protection services. Led by growth in respiratory protection, growth in protection and building and commercial services, we delivered sales growth of nearly 11%. Third quarter growth in local currency was 6.7%. Overall segment year-on-year sales growth was held back by almost 2%, due to our industrial minerals business which supplies mineral used on asphalt shingles for the U.S. residential housing market. As you are aware, housing in the U.S. remains very sluggish and our industrial minerals business is really a U.S-centric business. Geographically, sales growth was led by strong double-digit growth in Europe, followed by Latin America and Asia-Pacific. For those of you that attended our investor meeting last week got the opportunity to see the products and technologies of Rockford Thomson Equipment Ltd, a recent acquisition by our security business. Rockford Thomson is a manufacturer of optical character-recognition password readers used by airlines and immigration authorities headquartered in Newbury, U.K. The addition of Rockford Thomson enhances 3M secure document-scanning solutions portfolio and allows expansion in the transportation markets, such as international airlines. Operating income increased almost 11%, as the business continue to maintain consistent operating margins in excess of 20%. Year-to date sales have increased 16.6% with profits up 15.7%. Please turn to slide 14 to review the third quarter results for our final segment, Electrical Communications. The growth results in this business continue to be mixed. However, the financial results continue at record levels. We continue to experience strong growth in electrical markets and communications markets, which have been somewhat offset by declining growth in some of the products we supply in the consumer electronics market, which our end devices that have come to end of life, adversely impacting sales in our Electronic Solutions division. Electronics Markets Materials division started to see some recovery in the third quarter in consumer electronic applications, fueled by demand for fluids. Overall the electrical communications business has taken the necessary corrective actions to respond at the slowing consumer electronics market. As mentioned earlier, the Electronics Solutions division announced a consolidation manufacturing operations and reductions in structure, to allow the businesses strengthen their competitive position. At the same time, our electrical markets and communications businesses delivered a strong double-digit bottom line growth, offsetting the weakness we saw in the consumer electronics piece. Sales were up 7.6%, over the third quarter last year with local currency growth of 4.3%, including 110 basis points of growth from the acquisitions. Strong results continue in Europe and in the U.S. for communication and electrical markets. Outstanding cost discipline continues to generate profits that increased 16.4% over the same period last year, with margins up 1.5 percentage points to 19.6%. Year-to-date sales reflect a strong first half, with an increase of 4.9% and profits increased 13.5%, versus the first nine months of 2006. Please turn to slide 15, where I will review a few balance sheet and cash flow metrics. Excluding tax payments related to the gain and sale for the branded pharmaceutical business, free cash flow in the quarter was $693 million. This year-over-year cash flow drop is more than accounted for by higher tax payments. Third quarter free cash low includes a $200 million U.S. pension contribution, which is the primary driver for lower free cash flow from Q2. Both year-on-year and sequential working capital turns have stabilized at five turns. Capital expenditures totaled $379 million, an increase of $67 million year-on-year and $31 million sequentially. Year-to-date, we have invested greater than $1 billion in capital expenditures, on-track with our full year expectations of $1.4 billion to $1.5 billion. Dividend payments to our share holders were $343 million and we continue to buyback stock during the quarter, albeit at a slower pace than previous quarters, with gross share repurchases of $557 million. Weighted average diluted shares outstanding of 729.9 were down 3.5% year-on-year and down slightly sequentially. And finally, our debt-to-cap ratio was 32.3% at the end of the third quarter. This concludes my formal business review. Now, I would like to turn the call back over to George for his closing comments. George?